drugset / Trial / NCT02560376
68Ga-NOTA-exendin-4 PET/CT for the Localization of Insulinoma and Diagnosis of Nesidioblastosis
Phase 0
Unknown
100 enrolled
Peking Union Medical College Hospital
National Institute for Biomedical Imaging and Bioengineering (NIBIB) · collab
NaSingle-groupOpen-labelDiagnostic
Summary
This is an open-label positron emission tomography/computed tomography (PET/CT) study to investigate the diagnostic performance and evaluation efficacy of 68Ga-NOTA-exendin-4 in insulinoma and nesidioblastosis patients. A single dose of 55.5-111 Mega-Becquerel (MBq) 68Ga-NOTA-exendin-4 will be injected intravenously. Visual and semiquantitative method will be used to assess the PET/CT images.
Timeline
- Start
- 2014-02
- Primary completion
- 2016-12
- Completion
- 2016-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 68Ga-NOTA-exendin-4 | Diagnostic / imaging agent | 55.5 mbq | Intravenous |
| Subject | 68Ga-NOTA-exendin-4 | Diagnostic / imaging agent | 111 mbq | Intravenous |